Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

BACKGROUND: More than 50% of hepatitis C viruses (HCV)-infected patients do not respond to the classical Interferon (IFN)/Ribavirin (RBV) combination therapy. The aim of this study was to evaluate the efficacy of retreatment with Peg-Interferon alpha-2b (PEG-IFN alpha-2b) plus RBV, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçales, Fernando L, Moma, Camila A, Vigani, Aline G, Angerami, Adriana FCF, Gonçales, Eduardo SL, Tozzo, Raquel, Pavan, Maria HP, Gonçales, Neiva SL
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912909/
https://www.ncbi.nlm.nih.gov/pubmed/20646277
http://dx.doi.org/10.1186/1471-2334-10-212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912909/
https://www.ncbi.nlm.nih.gov/pubmed/20646277
http://dx.doi.org/10.1186/1471-2334-10-212

Ejemplares similares